Clinical Characteristics and Analysis of Pituitary Complex and Rare Diseases
The goal of this observational study is to systematically describe the clinical characteristics and outcomes of patients with pituitary complex and rare diseases at Peking Union Medical College Hospital. The main questions it aims to answer are:
- What are the influencing factors and rates of remission?
- What are the comorbidities associated with these diseases?
- What are the perioperative events, radiological findings, and pathological features?
Researchers will compare different patient groups to see if there are significant differences in these outcomes.
Participants will:
- Undergo detailed clinical evaluations.
- Provide medical history and data for analysis.
- Participate in follow-up assessments to monitor disease progression and treatment outcomes.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yong Yao, MD
- Phone Number: +8669152530
- Email: yaoyong@pumch.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Yong Yao, MD
- Phone Number: +8669152530
- Email: yaoyong@pumch.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosed with rare sellar diseases including but not limited to pituitary adenomas (such as Thyrotropin-secreting pituitary adenomas, GH-secreting adenomas), craniopharyngiomas, Rathke's cleft cysts, sellar region germ cell tumors, cavernous sinus syndrome, and other diseases
- Detailed medical history, including clinical symptoms, treatment plans and follow-up outcomes
Exclusion Criteria:
- Incomplete medical records, especially missing key imaging diagnostic results
- Patients with coexisting primary central nervous system diseases unrelated to sellar region diseases (such as severe traumatic brain injury)
- Patients whose sellar region pathological diagnosis was changed or overturned during the follow-up period
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Pituitary Complex and Rare Diseases
The Pituitary Complex and Rare Diseases cohort consists of patients diagnosed with various pituitary disorders, including but not limited to pituitary adenomas, craniopharyngiomas, Rathke's cleft cysts, sellar region germ cell tumors, cavernous sinus syndrome, and other diseases.
Patients requiring surgical resection or biopsy of pituitary pathologies will undergo transsphenoidal surgery or craniotomy.
|
Resection of pituitary pathologies.
Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Remission
Time Frame: Postoperative one week and extends to the latest follow-up, estimated at up to 3 years
|
Hormonal normalization and free of pathologies
|
Postoperative one week and extends to the latest follow-up, estimated at up to 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease Comorbidities
Time Frame: From patient admission to an evaluation period extending up to the latest follow-up, estimately up to 3 years
|
Systemic changes accompanied with Pituitary Complex and Rare Diseases
|
From patient admission to an evaluation period extending up to the latest follow-up, estimately up to 3 years
|
|
Postoperative complications
Time Frame: Postoperative one week and extends to the latest follow-up, estimated at up to 3 years
|
adverse events or medical issues that arise after a surgical procedure on the pituitary diseases.These complications can include various problems such as bleeding, infection, hormonal imbalances, cerebrospinal fluid leaks, vision changes, or neurological deficits
|
Postoperative one week and extends to the latest follow-up, estimated at up to 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yong Yao, MD, Department of Neurosurgery, Peking Union Medical College Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- K5112
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.